about
Galeterone for the treatment of advanced prostate cancer: the evidence to dateCell-free circulating tumor DNA in cancerResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerClonal origin and spread of metastatic prostate cancerCancer Evolution and the Limits of Predictability in Precision Cancer MedicinePersistent androgen receptor addiction in castration-resistant prostate cancerEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerGenomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancerEvolutionary determinants of cancerTranslational implications of tumor heterogeneityTargeting the adaptive molecular landscape of castration-resistant prostate cancerIntegrative clinical genomics of advanced prostate cancer.DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNovel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerClinical applications of liquid biopsies in gastrointestinal oncologyUsing circulating tumor cells to inform on prostate cancer biology and clinical utilityUnraveling the clonal hierarchy of somatic genomic aberrations.ASEQ: fast allele-specific studies from next-generation sequencing data.Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.New horizons in tumor microenvironment biology: challenges and opportunitiesTracking the origins and drivers of subclonal metastatic expansion in prostate cancer.Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNACancer in the parasitic protozoans Trypanosoma brucei and Toxoplasma gondii.Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationHeterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsEmerging concepts in liquid biopsiesAndrogen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen pathway resistance in prostate cancer and therapeutic implicationsSystematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based ApproachPruning Cancer's Evolutionary Tree with Lesion-Directed Therapy.Targeting the glucocorticoid receptor in breast and prostate cancers.Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer.BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patientsTesting for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Translational and clinical implications of the genetic landscape of prostate cancer.
P2860
Q26739887-5D7FAC03-2BDB-4F09-9854-B217A569F105Q26750899-7DF90481-E399-41EE-9A4E-35FD5D376CD4Q26751237-4E1BED08-7FC3-40E0-AFE0-85F346B8FE87Q26752873-05AFD779-588B-429A-B9C7-29757364AA40Q26767415-7BB609A8-1028-4542-B364-80BC13E47D8DQ26777163-1F7E7560-22E2-4C05-9E1B-5DD6BD56E179Q26777310-E899BC06-EDBE-4CF4-9D26-613B9DF381D5Q26778586-63CA7FBF-868C-406E-8AC1-531FCFD86332Q26801710-2F048CE0-D0CA-4560-AE43-C0F5A8167211Q26822823-A11A7DB1-86FA-488C-9FD6-20F1857B6E5DQ27022821-12FBE603-E009-46E6-A4A3-E40F36F1EFF2Q27853170-9D75ED2B-B088-47C0-833C-AA5DB6CFEEEEQ27853235-5896C046-D1E7-4D91-855E-07F32EDF8406Q28067556-D373F27D-FDD3-4D76-8BB7-EA293DF71558Q28073730-E72B5329-6631-4465-B5EA-D8937DC537FBQ28083261-C5D699ED-3A55-4DE1-878A-F5C0F49F9C95Q30587156-FAF49ECD-A539-49D2-98A6-71E998CD41D0Q30936481-4AF6CC69-D614-4DF0-9621-FD6FF643FEF2Q34478734-7A444567-DCC5-4B09-B510-9A8F05D6BC43Q34494714-FC60FF78-DECB-489A-AA17-634A8BD6BB39Q34528225-696CBA90-F9AB-4350-8C75-4B94873971A2Q34611922-8CD4F2CE-08D9-4521-A4DF-0FDC4A0B2E4CQ35151324-8DE08E75-3A6B-4E51-A377-603BE0717921Q35407284-3A46A1D8-FB5C-4ABA-8CCC-42BFCEF99C12Q35603660-C0F4300B-AF0E-491C-A3F2-3FF856C6B961Q35810461-2D56AA4C-EB0F-4C56-A723-EE3E86645484Q35895770-1CE6BAE7-8EC9-4842-A908-817F04A0D16FQ36087929-DF4409D8-5CB6-4E41-A2B8-56F74285C7C7Q36165598-E79E6B8D-CC6E-4AB5-8667-CF3B7516D98EQ36287422-B548F3A2-66F9-4861-9B05-154103E74D39Q36337259-49EC40EE-4DAC-4F38-BBA2-740A6D25EA7CQ36398998-D63011A0-70C4-4FFF-BE78-F8F012B8F3CCQ36416370-8BD72865-E7C9-4BAB-91CF-57A30E3B0C80Q36539506-9888B386-BAB8-42B2-99D1-03964046147AQ36560401-A2B9E0D2-4E92-4104-89E5-24FE1FA7835AQ36729300-DD7F1575-AD89-4B7E-BFC0-7F88391EA5A5Q36859396-AE987DA8-998D-4255-AAA1-6DE7AF99089DQ36905832-7CCC6B84-B132-46AA-A4AC-BB4473323418Q37242412-E87C2496-070D-4628-BBEA-A2B83FB40A1DQ37270512-DC3A8A91-2F54-4466-9C03-C3811EE8B543
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Tumor clone dynamics in lethal prostate cancer
@ast
Tumor clone dynamics in lethal prostate cancer
@en
type
label
Tumor clone dynamics in lethal prostate cancer
@ast
Tumor clone dynamics in lethal prostate cancer
@en
prefLabel
Tumor clone dynamics in lethal prostate cancer
@ast
Tumor clone dynamics in lethal prostate cancer
@en
P2093
P2860
P50
P1476
Tumor clone dynamics in lethal prostate cancer
@en
P2093
Aurelius Omlin
Carmel Pezaro
Daniel Nava Rodrigues
Emily Grist
Jane Goodall
Johann S de Bono
Nina Tunariu
Penelope Flohr
Roberta Ferraldeschi
P2860
P304
P356
10.1126/SCITRANSLMED.3009448
P407
P50
P577
2014-09-01T00:00:00Z